蔚蓝生物分析师会议 调研日期：2025年09月04日 调研行业：农牧饲渔 参与调研的机构：投资者网上提问等 / 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 扫码关注 调研纪要精选公众号 时尚悉各行业顶流企业周研情况。 LIST 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中: ...

Investment Rating - The report maintains a "Recommended" rating for the company [3][5]. Core Viewpoints - The company achieved a revenue of 652 million yuan in the first half of 2025, representing a year-on-year growth of 7.05%. However, the net profit attributable to the parent company decreased by 8.98% to 27 million yuan [1]. - The company has focused on innovation and increased its R&D investment to 64 million yuan, accounting for 9.80% of revenue, which is a 16.04% increase year-on-year [2]. - The company has completed its capacity layout, with various projects now in operation, enhancing its competitive edge and collaborative development across multiple business lines [3]. - The enzyme and probiotic industries have high barriers to entry, and the company is well-positioned as a representative player in these fields, with significant technological and platform advantages [3]. Financial Summary - The company expects net profits attributable to the parent company to be 74 million yuan, 81 million yuan, and 90 million yuan for the years 2025, 2026, and 2027, respectively [3]. - Earnings per share (EPS) are projected to be 0.29 yuan, 0.32 yuan, and 0.35 yuan for the same years, with corresponding price-to-earnings (PE) ratios of 50X, 46X, and 42X [3]. - Revenue is forecasted to grow from 1,431 million yuan in 2025 to 1,705 million yuan in 2027, with growth rates of 8.4%, 8.9%, and 9.4% respectively [9].